| Indication |
For the treatment of overactive bladder with symptoms of urge
urinary incontinence, urgency, and urinary frequency, detrusor
instability and frequency of micturition. |
| Pharmacodynamics |
Trospium is an antispasmodic, antimuscarinic agent indicated for
the treatment of overactive bladder with symptoms of urge urinary
incontinence, urgency, and urinary frequency. Receptor assays showed
that trospium has negligible affinity for nicotinic receptors as
compared to muscarinic receptors at concentrations obtained from
therapeutic doses. |
| Mechanism of action |
Trospium antagonizes the effect of acetylcholine on muscarinic
receptors in cholinergically innervated organs. Its parasympatholytic
action reduces the tonus of smooth muscle in the bladder. |
| Absorption |
9.6% |
| Volume of distribution |
|
| Protein binding |
50-85% |
| Metabolism |
Not fully defined |
| Route of elimination |
After administration of oral 14C-trospium chloride, the majority
of the dose (85.2%) was recovered in feces and a smaller amount (5.8% of
the dose) was recovered in urine; 60% of the radioactivity excreted in
urine was unchanged trospium. The mean renal clearance for trospium
(29.07 L/hour) is 4-fold higher than average glomerular filtration rate,
indicating that active tubular secretion is a major route of
elimination for trospium. SANCTURA ® is metabolized by ester hydrolysis
and excreted by the kidneys by a combination of tubular secretion and
glomerular filtration. |
| Half life |
20 hours |
| Clearance |
|
| Toxicity |
Not Available |
